600276 恒瑞医药
已收盘 07-26 15:00:00
资讯
新帖
简况
恒瑞医药最新公告:获得三款药物的临床试验批准通知书
证券之星 · 07-26 17:40
恒瑞医药最新公告:获得三款药物的临床试验批准通知书
恒瑞医药(600276.SH):相关产品获批开展治疗乳腺癌的临床试验
智通财经 · 07-26 17:38
恒瑞医药(600276.SH):相关产品获批开展治疗乳腺癌的临床试验
恒瑞医药07月26日主力资金流出1415万元 连续3日减仓
自选股智能写手 · 07-26 15:19
恒瑞医药07月26日主力资金流出1415万元 连续3日减仓
创新药产业招商清单:恒瑞医药、百济神州、信达生物等最新投资动向【附关键企业名录】
前瞻网 · 07-26 11:33
创新药产业招商清单:恒瑞医药、百济神州、信达生物等最新投资动向【附关键企业名录】
恒瑞医药7月25日遭北向资金减持81.34万股
自选股智能写手 · 07-26 09:30
恒瑞医药7月25日遭北向资金减持81.34万股
恒瑞医药07月25日收涨0.14% 主力资金逆市抛售
自选股智能写手 · 07-25 15:18
恒瑞医药07月25日收涨0.14% 主力资金逆市抛售
恒瑞医药“SHR8058”Ⅲ期临床结果即将公布
药智网 · 07-25 14:21
恒瑞医药“SHR8058”Ⅲ期临床结果即将公布
《大行》大摩列出亚太区喜爱高质素及低啤打值主题“增持”股份名单(表)
阿斯达克财经 · 07-25 12:49
《大行》大摩列出亚太区喜爱高质素及低啤打值主题“增持”股份名单(表)
恒瑞多项创新药研究数据密集披露,涉及肺癌、糖尿病、减重等多领域
新浪医药 · 07-25 10:52
恒瑞多项创新药研究数据密集披露,涉及肺癌、糖尿病、减重等多领域
恒瑞医药7月23日遭北向资金减持116.62万股
自选股智能写手 · 07-24
恒瑞医药7月23日遭北向资金减持116.62万股
恒瑞医药大跌3.09% 北向资金连续3日增持
智选洞察 · 07-23
恒瑞医药大跌3.09% 北向资金连续3日增持
恒瑞医药回应FDA警告信背后:销售费用高达75亿,市值较高点蒸发3000多亿元
消费日报网 · 07-23
恒瑞医药回应FDA警告信背后:销售费用高达75亿,市值较高点蒸发3000多亿元
北向资金7月22日净买入恒瑞医药316.03万股 连续3日增持
自选股智能写手 · 07-23
北向资金7月22日净买入恒瑞医药316.03万股 连续3日增持
恒瑞医药07月22日收涨1.28% 主力资金逆市抛售
自选股智能写手 · 07-22
恒瑞医药07月22日收涨1.28% 主力资金逆市抛售
恒瑞医药(600276.SH)及子公司获药物临床试验批准通知书
智通财经 · 07-21
恒瑞医药(600276.SH)及子公司获药物临床试验批准通知书
恒瑞医药(600276.SH):海曲泊帕乙醇胺片获药物临床试验批准通知书
智通财经 · 07-21
恒瑞医药(600276.SH):海曲泊帕乙醇胺片获药物临床试验批准通知书
恒瑞医药(600276.SH):羟乙磺酸达尔西利片、HRS-1358片获得药物临床试验批准
格隆汇资讯 · 07-21
恒瑞医药(600276.SH):羟乙磺酸达尔西利片、HRS-1358片获得药物临床试验批准
减肥药赛道“搅局者”来了,两大巨头“硬碰硬”
中国基金报 · 07-20
减肥药赛道“搅局者”来了,两大巨头“硬碰硬”
中欧医疗健康股票仓位升至三年最高 葛兰二季度十大重仓股出炉
澎湃新闻 · 07-19
中欧医疗健康股票仓位升至三年最高 葛兰二季度十大重仓股出炉
工银瑞信基金赵蓓二季报出炉!恒瑞医药(600276.SH)为第一重仓
智通财经 · 07-19
工银瑞信基金赵蓓二季报出炉!恒瑞医药(600276.SH)为第一重仓
加载更多
公司概况
公司名称:
江苏恒瑞医药股份有限公司
所属行业:
医药制造业
上市日期:
2000-10-18
主营业务:
江苏恒瑞医药股份有限公司主营业务涉及药品研发、生产和销售,主要产品是艾瑞昔布片、甲磺酸阿帕替尼片、硫培非格司亭注射液、马来酸吡咯替尼片、卡瑞利珠单抗、甲苯磺酸瑞马唑仑、氟唑帕利胶囊、海曲泊帕乙醇胺片、羟乙磺酸达尔西利片、脯氨酸恒格列净片、瑞维鲁胺片、阿得贝利单抗注射液、磷酸瑞格列汀片、富马酸泰吉利定注射液、林普利塞片、奥特康唑胶囊。报告期内,公司荣获中国医药质量管理协会颁发的“首批无菌药品质量保障企业”荣誉称号、江苏省医药质量管理协会颁发的“江苏省医药行业优秀质量管理企业”荣誉称号;公司“雏鹰QC小组”、“远志QC小组”被评为江苏省医药行业质量管理(QC)发表交流优秀小组。
发行价格:
11.98
{"stockData":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":41.07,"timestamp":1721977200000,"preClose":41.46,"halted":0,"volume":22115817,"delay":0,"floatShares":6379000000,"shares":6379000000,"eps":0.6949,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.39,"latestTime":"07-26 15:00:00","open":41.46,"high":41.58,"low":40.59,"amount":907000000,"amplitude":0.0239,"askPrice":41.08,"askSize":1,"bidPrice":41.07,"bidSize":129,"shortable":0,"etf":0,"ttmEps":0.6949,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1722216600000},"adr":0,"adjPreClose":41.46,"symbolType":"stock","openAndCloseTimeList":[[1721957400000,1721964600000],[1721970000000,1721977200000]],"highLimit":45.61,"lowLimit":37.31,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":6379002274,"pbRate":6.26,"roa":"--","roe":"3.33%","epsLYR":0.68,"committee":0.105546,"marketValue":261986000000,"floatMarketCap":261986000000,"peRate":59.102031,"changeRate":-0.0094,"turnoverRate":0.0035,"status":1,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2024-07-29。"},"requestUrl":"/m/hq/s/600276","defaultTab":"news","newsList":[{"id":"2454316392","title":"恒瑞医药最新公告:获得三款药物的临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2454316392","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454316392?lang=zh_cn&edition=full","pubTime":"2024-07-26 17:40","pubTimestamp":1721986835,"startTime":"0","endTime":"0","summary":"恒瑞医药公告,公司及子公司山东盛迪医药有限公司收到国家药监局核准签发关于HRS-1358片、HRS-8080片、HRS-6209胶囊的《药物临床试验批准通知书》,将于近期开展临床试验。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072600037739.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","LU1064131003.USD","LU2488822045.USD","BK0196","LU0405327148.USD","BK0183","LU0405327494.USD","600276","BK0188","LU2148510915.USD","03347","BK1576","BK1141","BK1583","LU1064130708.USD","BK0012","BK0028","BK0239","LU1328615791.USD"],"gpt_icon":0},{"id":"2454152323","title":"恒瑞医药(600276.SH):相关产品获批开展治疗乳腺癌的临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2454152323","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454152323?lang=zh_cn&edition=full","pubTime":"2024-07-26 17:38","pubTimestamp":1721986727,"startTime":"0","endTime":"0","summary":"智通财经APP讯,恒瑞医药(600276.SH)公告,近日,公司及子公司山东盛迪医药有限公司收到国家药品监督管理局(“国家药监局”)核准签发关于HRS-1358片、HRS-8080片、HRS-6209胶囊的《药物临床试验批准通知书》,同意HRS-6209联合HRS-1358或HRS-8080或芳香化酶抑制剂或氟维司群用于乳腺癌的治疗的临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1156153.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0405327148.USD","BK0060","LU2488822045.USD","600276","BK1576","LU1064131003.USD","BK0028","LU1064130708.USD","03347","BK1141","BK0196","BK0012","BK0183","BK1583","LU2148510915.USD","LU1328615791.USD","BK0239","LU0405327494.USD","BK0188"],"gpt_icon":0},{"id":"2454639985","title":"恒瑞医药07月26日主力资金流出1415万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2454639985","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454639985?lang=zh_cn&edition=full","pubTime":"2024-07-26 15:19","pubTimestamp":1721978397,"startTime":"0","endTime":"0","summary":"07月26日, 恒瑞医药股价跌0.94%,报收41.07元,成交金额9.07亿元,换手率0.35%,振幅2.39%,量比0.80。恒瑞医药今日主力资金净流出1415万元,连续3日净流出,上一交易日主力净流出4100万元,今日环比减少65.49%。该股近5个交易日下跌2.75%,主力资金累计净流出1.62亿元,其中2个交易日为股价上涨时净流出;近20日主力资金累计净流出1.38亿元,其中净流出天数为13日。净流出前三个股分别为华东医药、百济神州-U、恒瑞医药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407261536409eec8781&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407261536409eec8781&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1064130708.USD","BK0183","BK0188","BK0028","LU0405327148.USD","BK0239","LU2148510915.USD","LU2488822045.USD","LU1328615791.USD","LU1064131003.USD","BK0012","BK0196","LU0405327494.USD","600276","BK0060"],"gpt_icon":0},{"id":"2454368766","title":"创新药产业招商清单:恒瑞医药、百济神州、信达生物等最新投资动向【附关键企业名录】","url":"https://stock-news.laohu8.com/highlight/detail?id=2454368766","media":"前瞻网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454368766?lang=zh_cn&edition=full","pubTime":"2024-07-26 11:33","pubTimestamp":1721964782,"startTime":"0","endTime":"0","summary":"创新药行业又迎来了重大利好。从已上市的自主研发产品数量来看,截至2023年8月,恒瑞医药已上市的自主研发产品数量最多,达到13个;其次是信达生物,为10个。其中抗肿瘤、手术麻醉、造影剂等领域市场份额在行业内名列前茅。在全球制药企业TOP50榜单中,恒瑞医药连续三年上榜,排名逐年攀升至第38位。2020中国化学制药行业创新型优秀企业品牌TOP10中,恒瑞医药位列第一位。目前,恒瑞医药的抗肿瘤药产品主要包括卡培他滨片、来曲唑片等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407261143379eebe4db&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407261143379eebe4db&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1588","BK1583","BK1589","BK1500","BK1574","01801","06160","06978","688235","LU0307460666.USD","LU0588546209.SGD","LU1969619763.USD","BGNE","600276","LU2328871848.SGD"],"gpt_icon":0},{"id":"2454355300","title":"恒瑞医药7月25日遭北向资金减持81.34万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2454355300","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454355300?lang=zh_cn&edition=full","pubTime":"2024-07-26 09:30","pubTimestamp":1721957411,"startTime":"0","endTime":"0","summary":"7月25日,北向资金减持恒瑞医药81.34万股。截止当日收盘,沪股通共持有恒瑞医药37909.58万股,占流通股5.94%。沪股通减持金额前五个股分别为贵州茅台、工商银行、工业富联、长江电力、中国平安。恒瑞医药近5个交易日下跌1.64%,沪股通累计增持171.98万股;近20个交易日上涨5.66%,沪股通累计减持1006.23万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240726093049955bb670&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240726093049955bb670&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","BK0239","LU1064130708.USD","LU1064131003.USD","LU2488822045.USD","BK0183","BK0028","BK0060","LU1328615791.USD","BK0012","LU2148510915.USD","BK0196","600276","LU0405327148.USD","LU0405327494.USD"],"gpt_icon":0},{"id":"2454981780","title":"恒瑞医药07月25日收涨0.14% 主力资金逆市抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2454981780","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454981780?lang=zh_cn&edition=full","pubTime":"2024-07-25 15:18","pubTimestamp":1721891891,"startTime":"0","endTime":"0","summary":"07月25日, 恒瑞医药股价涨0.14%,报收41.46元,成交金额9.09亿元,换手率0.34%,振幅2.85%,量比0.74。恒瑞医药今日主力资金净流出4100万元,上一交易日主力净流出1623万元,今日环比增加152.62%。该股近5个交易日下跌1.64%,主力资金累计净流出2.67亿元,其中3个交易日为股价上涨时净流出;近20日主力资金累计净流出2.16亿元,其中净流出天数为13日。净流出前三个股分别为新和成、恒瑞医药、国药现代。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407251523499ee8e82f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407251523499ee8e82f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1064130708.USD","BK0196","LU1328615791.USD","LU0405327148.USD","BK0183","600276","BK0188","LU1064131003.USD","LU0405327494.USD","BK0012","LU2148510915.USD","BK0239","BK0028","LU2488822045.USD","BK0060"],"gpt_icon":0},{"id":"2454581185","title":"恒瑞医药“SHR8058”Ⅲ期临床结果即将公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2454581185","media":"药智网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454581185?lang=zh_cn&edition=full","pubTime":"2024-07-25 14:21","pubTimestamp":1721888500,"startTime":"0","endTime":"0","summary":"此次大会, 恒瑞医药 引进的干眼病 创新药 全氟己基辛烷滴眼液国内三期临床研究Post-hoc(事后)分析研究结果成功被接收。这意味着,恒瑞医药眼科产品将首次亮相国际学术会议,展现公司眼科创新药领域卓越成果的同时,也有望为SHR8058治疗干眼症积累更多医学证据。作为1类创新药,SHR8058在国内三期临床研究中表现出良好的治疗效果,8周相比对照组可显著改善干眼症状和体征1。此外,防控儿童近视进展的HR19034滴眼液正在开展III期临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072514303695590300&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072514303695590300&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2148510915.USD","BK0060","BK0239","BK0028","BK0183","BK0188","LU0405327494.USD","LU2488822045.USD","BK0196","LU1064131003.USD","LU1328615791.USD","BK0012","600276","LU0405327148.USD","LU1064130708.USD"],"gpt_icon":0},{"id":"2454890177","title":"《大行》大摩列出亚太区喜爱高质素及低啤打值主题“增持”股份名单(表)","url":"https://stock-news.laohu8.com/highlight/detail?id=2454890177","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454890177?lang=zh_cn&edition=full","pubTime":"2024-07-25 12:49","pubTimestamp":1721882940,"startTime":"0","endTime":"0","summary":"摩根士丹利发表亚太策略报告,建议降打啤打值及对亚太区半导体板块先行获利,并列出亚太区喜爱的高质素及低啤打值主题“增持”股份名单,现列出其中港股、A股及中概股:股份理想汽车-W海底捞华润万象生活中国重汽贵州茅台拼多多五粮液恒瑞医药韦尔股份成都银行新产业 (港股报价延迟最少十五分钟。沽空资料截至 2024-07-25 12:25。) (A股报价延迟最少十五分钟。) (美股为即时串流报价; OTC市场股票除外,资料延迟最少15分钟。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180406101527187_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180406101527187_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1366247/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU0405327494.USD","LU0211977185.USD","159982","601838","LU0862451753.SGD","BK1539","LU2488822045.USD","LU0918141887.USD","01209","BK0028","LI","LU0328353924.USD","LU0072913022.USD","LU0048580855.USD","LU0873338254.USD","LU1781817850.SGD","399300","LU0516422366.SGD","LU0890818403.SGD","BK0278","LU0456827905.SGD","02015","300832","LU0856984785.SGD","PDD","BK1583","000858","LU0051755006.USD","LU0605514214.HKD","LU0577902538.SGD","LU0320764599.SGD","LU1969619763.USD","LU1794554557.SGD","LU0348805143.USD","600276","LU0819121731.USD","BK1542","06862","603501","LU0067412154.USD","BK1119","LU0878005551.USD","LU1008478684.HKD","BK1548","600519","LU0052750758.USD","BK0015","LU0456846285.SGD","LU1808992512.USD","LU0708995583.HKD","03808"],"gpt_icon":1},{"id":"2454358697","title":"恒瑞多项创新药研究数据密集披露,涉及肺癌、糖尿病、减重等多领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2454358697","media":"新浪医药","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454358697?lang=zh_cn&edition=full","pubTime":"2024-07-25 10:52","pubTimestamp":1721875952,"startTime":"0","endTime":"0","summary":"近日,恒瑞医药于国际知名医学期刊《STTT》披露了其自主研发的ADC创新药SHR-A1811单药用于既往经治HER2突变晚期非小细胞肺癌的研究数据。[1]梳理公开信息,这一个月以来,恒瑞医药密集披露了多项创新药研究数据,既涉及SHR-A1811、SHR-1701、HR17031、HRS9531等多个临床阶段创新产品,也有已上市的创新产品卡瑞利珠单抗,涵盖肺癌、食管鳞癌、直肠癌、糖尿病、减重等多个疾病领域。热门的GLP-1赛道是恒瑞在代谢性疾病领域的重要布局。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072511141795588bdc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072511141795588bdc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0405327494.USD","LU1328615791.USD","600276","LU0405327148.USD","BK0183","BK0196","LU1064131003.USD","LU2148510915.USD","BK0188","BK0012","BK0060","BK0028","LU1064130708.USD","LU2488822045.USD","BK0239","159992"],"gpt_icon":0},{"id":"2453011779","title":"恒瑞医药7月23日遭北向资金减持116.62万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2453011779","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453011779?lang=zh_cn&edition=full","pubTime":"2024-07-24 09:30","pubTimestamp":1721784609,"startTime":"0","endTime":"0","summary":"7月23日,北向资金减持恒瑞医药116.62万股。截止当日收盘,沪股通共持有恒瑞医药37982.19万股,占流通股5.95%。恒瑞医药近5个交易日上涨1.12%,沪股通累计增持155.29万股;近20个交易日上涨4.31%,沪股通累计减持835.53万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240724093046955490cf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240724093046955490cf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0196","LU1328615791.USD","LU2488822045.USD","LU0405327148.USD","BK0239","LU1064130708.USD","BK0060","BK0188","BK0183","600276","LU0405327494.USD","LU2148510915.USD","LU1064131003.USD","BK0028","BK0012"],"gpt_icon":0},{"id":"2453708295","title":"恒瑞医药大跌3.09% 北向资金连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2453708295","media":"智选洞察","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453708295?lang=zh_cn&edition=full","pubTime":"2024-07-23 14:28","pubTimestamp":1721716082,"startTime":"0","endTime":"0","summary":"资金动向截止发稿,恒瑞医药获得主力净流出2968万元,其中超大单流出2599万元,大单流出368万元。北向资金方面,恒瑞医药07月22日获得北向资金增持316.03万股,连续3日增持,截至07月22日,北向资金当前共持有恒瑞医药38098.81万股,市值157.92亿元,持股占流通股比为5.97%。最新财报显示,今年一季报,恒瑞医药实现营业收入59.98亿元,同比增长9.20%,净利润为13.69亿元,同比增长10.48%,基本每股收益为0.21元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240723142838aefaea31&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240723142838aefaea31&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0060","LU1064131003.USD","LU2488822045.USD","600276","LU1328615791.USD","BK0012","BK0188","LU1064130708.USD","BK0196","BK0028","BK0239","LU0405327148.USD","LU2148510915.USD","BK0183","LU0405327494.USD"],"gpt_icon":0},{"id":"2453775109","title":"恒瑞医药回应FDA警告信背后:销售费用高达75亿,市值较高点蒸发3000多亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2453775109","media":"消费日报网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453775109?lang=zh_cn&edition=full","pubTime":"2024-07-23 11:25","pubTimestamp":1721705113,"startTime":"0","endTime":"0","summary":"消费日报网讯近日,江苏恒瑞医药股份有限公司收到美国食品药品监督管理局现场检查报告后,其又收到了FDA的警告信。16日晚间,恒瑞医药回应称,本次FDA警告信中指出的问题没有影响到药品质量安全。此外,恒瑞医药的销售费用连年高企。此外,二级市场方面,截至目前,恒瑞医药的市值也从2021年最高峰时的6200亿元,下跌至约2680亿元,市值蒸发超3500亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407231127259ee100ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407231127259ee100ae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","LU2148510915.USD","LU0405327148.USD","LU1328615791.USD","BK0028","BK0060","BK0183","600276","LU1064130708.USD","LU0405327494.USD","LU1064131003.USD","BK0196","BK0012","BK0239","LU2488822045.USD"],"gpt_icon":0},{"id":"2453725721","title":"北向资金7月22日净买入恒瑞医药316.03万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2453725721","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453725721?lang=zh_cn&edition=full","pubTime":"2024-07-23 09:30","pubTimestamp":1721698210,"startTime":"0","endTime":"0","summary":"7月22日, 北向资金增持恒瑞医药316.03万股,连续3日增持。截止当日收盘,沪股通共持有恒瑞医药38098.81万股,占流通股5.97%。沪股通增持金额前五个股分别为紫金矿业、北汽蓝谷、工业富联、中金黄金、陕西煤业。恒瑞医药近5个交易日上涨4.88%,沪股通累计增持561.22万股;近20个交易日上涨6.16%,沪股通累计减持390.49万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407230931059ee0b309&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407230931059ee0b309&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1064130708.USD","BK0196","LU1328615791.USD","LU0405327148.USD","BK0183","600276","BK0188","LU1064131003.USD","LU0405327494.USD","BK0012","LU2148510915.USD","BK0239","BK0028","LU2488822045.USD","BK0060"],"gpt_icon":0},{"id":"2453373722","title":"恒瑞医药07月22日收涨1.28% 主力资金逆市抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2453373722","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453373722?lang=zh_cn&edition=full","pubTime":"2024-07-22 15:17","pubTimestamp":1721632672,"startTime":"0","endTime":"0","summary":"07月22日, 恒瑞医药股价涨1.28%,报收42.77元,成交金额13.91亿元,换手率0.51%,振幅2.96%,量比1.18。恒瑞医药今日主力资金净流出1.30亿元,连续3日净流出,上一交易日主力净流出1.19亿元,今日环比增加9.32%。该股近5个交易日上涨4.88%,主力资金累计净流出3.07亿元;近20日主力资金累计净流出2.14亿元,其中净流出天数为13日。净流出前三个股分别为恒瑞医药、人福医药、华东医药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072215211695e772fb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072215211695e772fb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0196","LU1328615791.USD","LU2488822045.USD","LU0405327148.USD","BK0239","LU1064130708.USD","BK0060","BK0188","BK0183","600276","LU0405327494.USD","LU2148510915.USD","LU1064131003.USD","BK0028","BK0012"],"gpt_icon":0},{"id":"2453422307","title":"恒瑞医药(600276.SH)及子公司获药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2453422307","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453422307?lang=zh_cn&edition=full","pubTime":"2024-07-21 16:28","pubTimestamp":1721550493,"startTime":"0","endTime":"0","summary":"智通财经APP讯,恒瑞医药(600276.SH)公告,近日,公司及子公司山东盛迪医药有限公司收到国家药品监督管理局(简称“国家药监局”)核准签发关于羟乙磺酸达尔西利片、HRS-1358片的《药物临床试验批准通知书》,将于近期开展临床试验。根据《中华人民共和国药品管理法》及有关规定,经审查,2024年4月23日受理的羟乙磺酸达尔西利片和2024年4月19日受理的HRS-1358片临床试验申请符合药品注册的有关要求,同意羟乙磺酸达尔西利片联合HRS-1358片开展用于乳腺癌的临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1153604.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600276","BK0060","03347","BK1141","LU1064130708.USD","BK0028","BK0188","BK0239","BK1576","LU0405327148.USD","LU1064131003.USD","LU0405327494.USD","BK0012","LU2148510915.USD","BK0183","BK0196","BK1583","LU2488822045.USD","LU1328615791.USD"],"gpt_icon":0},{"id":"2453223091","title":"恒瑞医药(600276.SH):海曲泊帕乙醇胺片获药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2453223091","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453223091?lang=zh_cn&edition=full","pubTime":"2024-07-21 16:25","pubTimestamp":1721550354,"startTime":"0","endTime":"0","summary":"智通财经APP讯,恒瑞医药(600276.SH)公告,公司收到国家药品监督管理局(简称“国家药监局”)核准签发关于海曲泊帕乙醇胺片的《药物临床试验批准通知书》,将于近期开展临床试验。根据《中华人民共和国药品管理法》及有关规定,经审查,2024年4月17日受理的海曲泊帕乙醇胺片临床试验申请符合药品注册的有关要求,同意本品开展“计划接受有创性操作或手术的慢性肝病伴血小板减少症的成年患者”的临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1153602.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","LU2488822045.USD","LU0405327148.USD","LU1064130708.USD","BK0188","03347","BK1583","LU2148510915.USD","BK0183","600276","BK0239","BK0196","BK0012","LU0405327494.USD","BK0028","BK0060","LU1328615791.USD","BK1141","LU1064131003.USD"],"gpt_icon":0},{"id":"2453239262","title":"恒瑞医药(600276.SH):羟乙磺酸达尔西利片、HRS-1358片获得药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2453239262","media":"格隆汇资讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453239262?lang=zh_cn&edition=full","pubTime":"2024-07-21 15:59","pubTimestamp":1721548777,"startTime":"0","endTime":"0","summary":"格隆汇7月21日丨恒瑞医药(600276.SH)发布公告,近日,公司及子公司山东盛迪医药有限公司收到国家药监局核准签发关于羟乙磺酸达尔西利片、HRS-1358片的《药物临床试验批准通知书》,将于近期开展临床试验。羟乙磺酸达尔西利片(商品名:艾瑞康)已获批上市两个适应症,分别为:2021年12月,获批适应症为联合氟维司群用于激素受体(HR)阳性,人表皮生长因子受体2(HER2)阴性的经内分泌治疗后进展的复发或转移性乳腺癌的治疗;2023年6月,获批适应症为联合芳香化酶抑制剂作为初始治疗,适用于激素受体(HR)阳性,人表皮生长因子受体2(HER2)阴性局部晚期或转移性乳腺癌患者的治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072116010295e4c67e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072116010295e4c67e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","LU1064130708.USD","600276","LU0405327494.USD","BK0183","BK0196","LU1064131003.USD","BK0188","LU0405327148.USD","LU2148510915.USD","LU1328615791.USD","BK0028","BK0060","BK0012","LU2488822045.USD"],"gpt_icon":0},{"id":"2452405946","title":"减肥药赛道“搅局者”来了,两大巨头“硬碰硬”","url":"https://stock-news.laohu8.com/highlight/detail?id=2452405946","media":"中国基金报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452405946?lang=zh_cn&edition=full","pubTime":"2024-07-20 00:14","pubTimestamp":1721405689,"startTime":"0","endTime":"0","summary":"中国基金报记者 冯尧国内减重赛道迎来重磅级“选手”。一直以来,礼来与诺和诺德并称“GLP-1双雄”,后者拥有“减肥神药”司美格鲁肽,已在国内获批上市。如今,随着替尔泊肽加入国内减重赛道,两大巨头将在国内“硬碰硬”。如今,随着礼来的替尔泊肽注射液在国内获批,诺和诺德和礼来两大巨头在中国百亿元级GLP-1市场的正面较量也正式展开。目前,在减重赛道上,国内企业竞争激烈。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072000172295ddb277&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072000172295ddb277&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["603087","LU2148510915.USD","BK0060","BK0239","BK0028","BK0183","BK0188","LU0405327494.USD","688166","LU2488822045.USD","BK0196","LU1064131003.USD","LU1328615791.USD","BK0012","600276","LU0405327148.USD","LLY","LU1064130708.USD"],"gpt_icon":0},{"id":"2452423260","title":"中欧医疗健康股票仓位升至三年最高 葛兰二季度十大重仓股出炉","url":"https://stock-news.laohu8.com/highlight/detail?id=2452423260","media":"澎湃新闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452423260?lang=zh_cn&edition=full","pubTime":"2024-07-19 17:12","pubTimestamp":1721380320,"startTime":"0","endTime":"0","summary":" 中欧医疗健康股票仓位升至三年最高水平!7月19日,中欧基金葛兰在管的3只公募基金披露2024年二季报,其持仓情况也随之浮出水面。 截至2024年二季度末,葛兰在管公募基金规模约为407.65亿元,相较于一季度末时的458.74亿元,下降11.14%。 股票仓位方面,葛兰在2024年二季度小幅度提升了中欧医疗健康的股票仓位,由原本的92.79%升至93.73%,这已是该基金三年来最高水平;另外2只基金的股票仓位则小幅度下降。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-07-19/doc-inceshny5448585.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-07-19/doc-inceshny5448585.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["SG9999001093.SGD","000423","300347","300760","002475","LU0456827905.SGD","BK1219","LU0871576103.HKD","09926","02273","000568","IE00BMPRXN33.USD","LU0327786744.USD","002371","BK0236","300308","600519","605333","LU1781817850.SGD","300759","603259","LU2488822045.USD","300502","LU1880383366.USD","600276","300015","LU2148510915.USD","600085","BK0187","LU0531971595.HKD","LU0577902371.SGD","LU0880133367.SGD","300274","BK0028","603456","600436","600938","HK0000306701.USD","LU0359202008.SGD","LU0516423091.SGD","LU1051769294.HKD","BK0171","02269","LU0320764599.SGD","000921","000999","601127","HK0000306685.HKD","LU0594300179.USD","IE00B543WZ88.USD"],"gpt_icon":0},{"id":"2452490687","title":"工银瑞信基金赵蓓二季报出炉!恒瑞医药(600276.SH)为第一重仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2452490687","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452490687?lang=zh_cn&edition=full","pubTime":"2024-07-19 11:46","pubTimestamp":1721360796,"startTime":"0","endTime":"0","summary":"从最新的重点持仓股来看,截至二季度末,工银瑞信前沿医疗股票基金的十大重仓股分别为恒瑞医药、迈瑞医疗、东阿阿胶、科伦药业、华润三九、华润双鹤、信立泰、华东医药、鱼跃医疗、昆药集团。其中,鱼跃医疗、昆药集团和信立泰为二季度新进重仓股,爱尔眼科、智飞生物、百洋医药则退出了前十大重仓股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1153040.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0405327494.USD","LU1064130708.USD","BK0188","LU2488822045.USD","600276","LU0405327148.USD","BK0060","BK0183","BK0239","LU2148510915.USD","BK0012","BK0196","LU1064131003.USD","BK0028","LU1328615791.USD"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2000-10-18","address":"江苏省连云港市连云区经济技术开发区黄河路38号","stockEarnings":[{"period":"1week","weight":-0.0275},{"period":"1month","weight":0.0345},{"period":"3month","weight":-0.095},{"period":"6month","weight":0.0242},{"period":"1year","weight":-0.1421},{"period":"ytd","weight":-0.0874}],"companyName":"江苏恒瑞医药股份有限公司","boardCode":"AI0027","perCapita":"14482股","boardName":"医药制造业","registeredCapital":"637900万元","compareEarnings":[{"period":"1week","weight":-0.0307},{"period":"1month","weight":-0.0275},{"period":"3month","weight":-0.064},{"period":"6month","weight":-0.0066},{"period":"1year","weight":-0.1013},{"period":"ytd","weight":-0.0282}],"survey":" 江苏恒瑞医药股份有限公司主营业务涉及药品研发、生产和销售,主要产品是艾瑞昔布片、甲磺酸阿帕替尼片、硫培非格司亭注射液、马来酸吡咯替尼片、卡瑞利珠单抗、甲苯磺酸瑞马唑仑、氟唑帕利胶囊、海曲泊帕乙醇胺片、羟乙磺酸达尔西利片、脯氨酸恒格列净片、瑞维鲁胺片、阿得贝利单抗注射液、磷酸瑞格列汀片、富马酸泰吉利定注射液、林普利塞片、奥特康唑胶囊。报告期内,公司荣获中国医药质量管理协会颁发的“首批无菌药品质量保障企业”荣誉称号、江苏省医药质量管理协会颁发的“江苏省医药行业优秀质量管理企业”荣誉称号;公司“雏鹰QC小组”、“远志QC小组”被评为江苏省医药行业质量管理(QC)发表交流优秀小组。","serverTime":1722046033490,"listedPrice":11.98,"stockholders":"440465人(较上一季度减少5.31%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,600276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}